Article Text

Download PDFPDF

518 Discovery of MACO-355, a novel, first in mechanism ligand-blocking independent anti-LILRB1/2 monoclonal antibody for cancer therapy
  1. Krzysztof B Wicher1,
  2. Moritz Haneklaus1,
  3. Alicia Poindron1,
  4. Martha Lopez-Yrigoyen2,
  5. Carmen Rodriguez Seoane2,
  6. Maikel Fransen1,
  7. Chantell Payton1,
  8. Stephane Guillame1,
  9. Luca Cassetta2,
  10. Stephen Myatt1,2 and
  11. Carola Ries1,2
  1. 1Macomics, Cambridge, UK
  2. 2Macomics, Edinburgh, UK
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Macrophages populate most solid tumors in large numbers and limit effective anti-tumoral immune responses.1 The immunoreceptor tyrosine-based inhibitory motifs (‘ITIMs’) containing leukocyte immunoglobulin-like receptors (LILR) B1 and LILRB2 are expressed on tumour associated macrophages.2 Despite sharing multiple ligands such as major histocompatibility complex class I G (HLA-G), LILRB1 regulates phagocytosis, whereas blocking of LILRB2 ligand binding was shown to enhance cytokine release.3 To date, therapeutic approaches to targeting LILRB1 and LILRB2 have blocked receptor – ligand interaction to relieve ligand-mediated immune suppression. To obtain antibodies with novel and possibly superior LILRB1/LILRB2 modulating activity we investigated both ligand blocking and non ligand-blocking clones.

Methods Fully human antibodies were identified via immunization of mice with the full length ectodomain of LILRB1 but were screened for LILRB2-mediated reprogramming effects to identify dual LILRB1 and LILRB2 targeting antibodies. Antibodies were assessed for LILR family member binding, ligand neutralization, and functional activity in a range of macrophage cell assays including T cell suppression and tumour cell cocultures. Reprogramming was tested under immune suppressive conditions (such as colony-stimulating factor (CSF) 1, transforming growth factor beta (TGFb), interleukin (IL) 10).

Results We have identified MACO-355, a novel, dual LILRB1 and LILRB2 targeting antibody that does not block ligand binding capable of mediating macrophage reprogramming under strong immune suppressive conditions. MACO-355 was selected from the pool of LILRB1 and LILRB2 binders with the most potent macrophage reprogramming activity. Surprisingly, these antibodies do not neutralize ligand (HLA-G, HLA-A, HLA-E) binding to LILRB1/2. Nevertheless, they induce macrophage phagocytosis irrespectively of tumour ligand expression status and retain NK and T cell activation via LILRB1. Notably, MACO-355 was unique amongst identified macrophage reprogramming antibodies in being able to stimulate pro-inflammatory cytokine production by immune suppressed macrophages such as IL10 and TGFb treated or cancer cell coculture. Concordantly, stimulation of cells with MACO-355 also resulted in significantly higher levels of T cell expansion, proliferation, and interferon gamma release in a macrophage/T cell coculture suppression assay. Molecular studies showed MACO-355 binds a novel epitope in domain D3-D4 on LILRB1/2 resulting in pronounced modulation of intracellular kinase signaling.

Conclusions MACO-355 is a first in mechanism ligand-blocking independent LILRB1/2 antibody and is highly potent in macrophage reprogramming under tumour-like immune suppressed conditions. These data support the future clinical evaluation of MACO-355 as a cancer therapeutic.


  1. Ries CH, Cannarile MA, Hoves S, Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014; 25:846–859

  2. Colonna M , Samaridis J, Cella M, Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol. 1998; 160:3096–3100.

  3. Carosella D, Gregori S, Tronik-Le Roux D, HLA-G/LILRBs: A Cancer Immunotherapy Challenge. Trends in Cancer. 2021; 7:389–392

Ethics Approval The use of human material in this study (IRAS project ID: 311780) was approved by the East Midlands – Derby Research Ethics Committee.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.